Association between SSRI-Induced Sexual Dysfunction and Emotional Blunting in Women Treated with Sertraline: A Pilot Stratified Cross-Sectional Comparative Study

Background & Objectives: Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating major depressive disorder (MDD) but are frequently associated with adverse effects such as sexual dysfunction and emotional blunting. Despite their high prevalence, the potential correlation between these two domains remains underexplored. To investigate the relationship between sexual dysfunction and emotional blunting in female patients with MDD in remission under long-term sertraline therapy. Methods In this cross-sectional pilot study, 22 women in remission from major depressive disorder and receiving long-term sertraline treatment were compared to 20 age-matched healthy controls. Participants completed the Female Sexual Function Index (FSFI) and the Laukes Emotional Intensity Scale (LEIS). Between-group comparisons were performed using independent samples t-tests. Pearson correlation analysis was conducted to assess the relationship between sexual function and emotional blunting in the sertraline group. Statistical analysis was conducted using SPSS v26, with significance set at p < 0.05. Results A significant negative correlation was found between total FSFI scores and LEIS scores (r = − 0.68, p < 0.001), indicating that poorer sexual function was associated with greater emotional blunting. This association was consistent across FSFI subdomains, particularly in desire, arousal, and orgasm. Participants with more severe sexual dysfunction reported markedly reduced emotional intensity, despite being in depressive remission. Conclusion These findings suggest a strong relationship between SSRI-induced sexual dysfunction and emotional blunting, likely reflecting a shared neurobiological mechanism. Recognizing this overlap is essential for clinicians managing SSRI-treated patients. Routine screening for both side effects and personalized treatment strategies may improve patient adherence, quality of life, and overall therapeutic satisfaction.